About Chiltern
Chiltern is a company based in Sacramento (United States) founded in 1986 was acquired by Chiltern International in July 2014. Chiltern has completed 1 acquisition, including Nexus Oncology. Chiltern operates in a competitive market with competitors including Helsinn, Aster Insights, CancerVax, Abogen Biosciences and OnCusp, among others.
- Headquarter Sacramento, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$4.5 M (USD), Debt – Conventional
Jan 31, 2012
-
Investors
Chiltern International
& 1 more
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Chiltern International
(Jul 15, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Chiltern
Investors in Chiltern
Chiltern has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Chiltern International and Spring Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Flexible junior capital solutions are offered to growing businesses.
|
Locked | Locked | Locked | |
|
Full service CRO with expertise in oncology related development services
|
Locked | Locked | Locked |
Investor details for Chiltern
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chiltern
Chiltern has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nexus Oncology.
Investment portfolio details for Chiltern
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Specialist oncology clinical research services for drug trials were provided.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Chiltern
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Chiltern
Detailed financials for Chiltern
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Chiltern Comparisons
Peer comparison for Chiltern
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Chiltern
Chiltern operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Helsinn, Aster Insights, CancerVax, Abogen Biosciences and OnCusp, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Oncology therapeutics are developed, manufactured, and commercialized by Helsinn.
|
|
| Locked | Locked | Locked |
Contract-based oncology clinical trial services are provided by Aster Insights.
|
|
| Locked | Locked | Locked |
Cancer vaccine research and development is conducted by CancerVax.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
CRO offering clinical development services for oncology drugs
|
|
| Locked | Locked | Locked |
Preclinical and clinical oncology drug development services are provided.
|
Detailed competitors of Chiltern
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Chiltern
Complete news archive for Chiltern
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chiltern
Chiltern was founded in 1986 and raised its 1st funding round 26 years after it was founded.
Chiltern is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Ockham was a full-service oncology CRO with headquarters in North America and Europe and a presence in 12 countries in 4 continents. The company claims to have conducted 350 oncology-related Phase I-III clinical trials since its inception. Ockhams service portfolio included Scientific Affairs, Clinical Operations, Feasibility, Medical Affairs, Data Management and Biometrics. They catered to the needs of biopharmaceutical and medical device companies trying to develop oncology therapies. Ockham acquired Nexus Oncology, a 120 member strong UK-based oncology CRO, conducting Phase I-III oncology clinical trials across Europe, North America and Australasia in 2012. Post their acquisition by Chiltern, they offer their services through Chiltern Oncology, one of the 3 major divisions of Chiltern.
Chiltern has made 1 acquisition, including Nexus Oncology.
Chiltern has 2 investors. Key investors include Chiltern International, and Spring Capital Partners.